Drug intelligence / Profile preview

FID 119515A

Development stage: Preclinical
Lead developer: Novartis
Modality: Small Molecules
Administration: Ophthalmic

Overview

FID 119515A is an investigational drug originally developed by Novartis targeting eye diseases, specifically evaluated for its effects on tear film integrity in adults with a history of dry eye. It has been compared in a clinical setting to existing artificial tear products for the improvement of tear film, suggesting use as a potential therapy for dry eye disease (keratoconjunctivitis sicca)[1][3]. The precise mechanism of action remains undisclosed in public sources, but it is developed for ophthalmological indications.

Targets

CFD (Complement Factor D)

Beyond the preview

Go deeper on FID 119515A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FID 119515A.

Explore the full profile